慢性创伤性脑病与创伤性脑损伤在体检测的新进展
本文综述慢性创伤性脑病(CTE)在体早期检测的影像学进展,涵盖结构性MRI、扩散MRI、放射性核素PET(如flortaucipir与18F-FDDNP)以及fMRI、MR波谱、磁敏感加权成像和单光子发射CT等方法。作者指出,现有在体CTE生物标志物数据有限且受选择偏倚限制,单一检测难以将CTE与阿尔茨海默病或额颞叶痴呆区分,但联合液体生物标志物、神经影像和基因检测可能使早期检测成为可能。
要点
- 扩散MRI与放射性核素PET有望辅助CTE的早期检测。
- flortaucipir与18F-FDDNP的结合模式与尸检神经原纤维缠结四期分布一致。
- 现有在体CTE生物标志物数据有限且受选择偏倚限制。
核心结论
- 神经影像正快速成为CTE早期检测的关键工具,并可能对CTE定量至关重要;联合液体生物标志物、神经影像和基因检测可能使早期检测成为可能。
研究设计与样本
- 综述,聚焦多种神经影像技术在CTE与创伤性脑损伤在体早期检测中的应用,包括结构性MRI、扩散MRI、放射性核素PET、fMRI、MR波谱、磁敏感加权成像、单光子发射CT、扩散张量成像和动脉自旋标记。
关键影像表现/征象
- 结构性MRI与扩散MRI的进展已证明能够测量与CTE相关的体积和白质异常。
- 使用flortaucipir和18F-FDDNP等放射性核素的研究显示,其结合模式与尸检神经原纤维缠结四期分布一致。
局限性
- 具有尸检确认的在体CTE生物标志物数据有限。
- 现有数据受选择偏倚限制。
- 单一检测不太可能足以正确诊断CTE并将其与其他神经退行性疾病如阿尔茨海默病或额颞叶痴呆区分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Chronic traumatic encephalopathy (CTE) is a neurodegenerative disorder that is of epidemic proportions in contact sports athletes and is linked to subconcussive and concussive repetitive head impacts (RHI). Although postmortem analysis is currently the only confirmatory method to diagnose CTE, there has been progress in early detection techniques of fluid biomarkers as well as in advanced neuroimaging techniques. Specifically, promising new methods of diffusion MRI and radionucleotide PET scans could aid in the early detection of CTE.The authors examine early detection methods focusing on various neuroimaging techniques. Advances in structural and diffusion MRI have demonstrated the ability to measure volumetric and white matter abnormalities associated with CTE. Recent studies using radionucleotides such as flortaucipir and 18F-FDDNP have shown binding patterns that are consistent with the four stages of neurofibrillary tangle (NFT) distribution postmortem. Additional research undertakings focusing on fMRI, MR spectroscopy, susceptibility-weighted imaging, and singlephoton emission CT are also discussed as are advanced MRI methods such as diffusiontensor imaging and arterial spin labeled. Neuroimaging is fast becoming a key instrument in early detection and could prove essential for CTE quantification. This review explores a global approach to in vivo early detection.Limited data of in vivo CTE biomarkers with postmortem confirmation are available. While some data exist, they are limited by selection bias. It is unlikely that a single test will be sufficient to properly diagnosis and distinguish CTE from other neurodegenerative diseases such as Alzheimer disease or Frontotemporal Dementia. However, with a combination of fluid biomarkers, neuroimaging, and genetic testing, early detection may become possible.
引用
- Dallmeier JD, Meysami S, Merrill DA, et al. Emerging advances of in vivo detection of chronic traumatic encephalopathy and traumatic brain injury. Br J Radiol. 2019. PMID: 31287716. doi:10.1259/bjr.20180925
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。